EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

First‐Line Third‐Generation EGFR Tyrosine Kinase Inhibitor Monotherapy for Advanced EGFR‐Mutated Non‐Small Cell Lung Cancer: A Systematic Review and Network Meta‐Analysis

Wei Du, Anlin Li, Bijing Xiao, Yunpeng Yang, Wenfeng Fang, Yan Huang, Shaodong Hong, Li Zhang

MedComm · 2025-11 · 6 (11)

DOI: 10.1002/mco2.70393 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift MedComm, online erschienen am 06.11.2025. Verfasst von Wei Du und 7 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oncology in South China Guangdong Provincial Clinical Research Center For Cancer Sun Yat-sen University Cancer Center Guangzh…. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Third‐generation (third‐gen) epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have revolutionized the management of advanced EGFR‐mutated non‐small cell lung cancer (NSCLC). However, a head‐to‐head comparison of efficacy and safety among third‐gen EGFR TKIs is lacking. Seven randomized controlled trials with 3012 patients were included. All third‐gen TKIs significantly prolonged progression‐free survival (PFS) compared to first‐generation (first‐gen) TKIs, with no significant differences in PFS or objective response rate among the third‐gen TKIs. Furmonertinib ranked highest for PFS (HR, 0.82; 95% credible intervals [CrI], 0.72–0.94). Aumolertinib demonstrated the best intracranial control (HR, 0.74; 95% CrI, 0.63–0.89). Osimertinib (HR, 0.90; 95% CrI, 0.83–0.99) and lazertinib (HR, 0.89; 95% CrI, 0.79–1.00) showed overall survival benefits over first‐gen TKIs. Furmonertinib, aumolertinib, and osimertinib had lower rates of severe treatment‐related adverse events (TRAEs), while befotertinib exhibited the highest risk of grade ≥3 TRAEs (RR, 3.96; 95% CrI, 2.35–7.17). This study is the first head‐to‐head comparison of third‐gen EGFR‐TKIs using a Bayesian network meta‐analysis, offering critical insights into efficacy and safety. Our results support personalized selection of third‐gen EGFR TKIs for patients with advanced EGFR‐mutated NSCLC, particularly for subpopulations with CNS metastases or different mutation subtypes.

Schlagwörter

Stichwörter der Autor:innen

Bayesian network meta‐analysisepidermal growth factor receptorfirst‐linenon‐small cell lung cancertyrosine kinase inhibitors

Autor:innen und Institutionen

  • State Key Laboratory of Oncology in South China Guangdong Provincial Clinical Research Center For Cancer Sun Yat-sen University Cancer Center Guangzhou China.
  • Department of Medical Oncology Sun Yat-sen University Cancer Center Guangzhou China.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Du, W., Li, A., Xiao, B., Yang, Y., Fang, W., Huang, Y., Hong, S., & Zhang, L. (2025). First‐Line Third‐Generation EGFR Tyrosine Kinase Inhibitor Monotherapy for Advanced EGFR‐Mutated Non‐Small Cell Lung Cancer: A Systematic Review and Network Meta‐Analysis. MedComm, 6(11). https://doi.org/10.1002/mco2.70393

Vancouver

Du W, Li A, Xiao B, Yang Y, Fang W, Huang Y, et al. First‐Line Third‐Generation EGFR Tyrosine Kinase Inhibitor Monotherapy for Advanced EGFR‐Mutated Non‐Small Cell Lung Cancer: A Systematic Review and Network Meta‐Analysis. MedComm. 2025;6(11). doi:10.1002/mco2.70393

BibTeX
@article{Du2025,
  author = {Du, Wei and Li, Anlin and Xiao, Bijing and Yang, Yunpeng and Fang, Wenfeng and Huang, Yan and Hong, Shaodong and Zhang, Li},
  title = {First‐Line Third‐Generation EGFR Tyrosine Kinase Inhibitor Monotherapy for Advanced EGFR‐Mutated Non‐Small Cell Lung Cancer: A Systematic Review and Network Meta‐Analysis},
  journal = {MedComm},
  year = {2025},
  volume = {6},
  number = {11},
  doi = {10.1002/mco2.70393}
}
Kostenlos starten →